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Objectives Because excess adiposity is one of the most important determinants of adipokines and inflammatory factors
associated with coronary plaque rupture, we hypothesized that obesity was associated with myocardial infarction
at earlier ages.
Background The developing obesity pandemic of the past 50 years has gained considerable attention as a major public
health threat.
Methods The CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with
Early Implementation of the American College of Cardiology/American Heart Association Guidelines) regis-
try was a voluntary observational data collection and quality improvement initiative that began in November
2001, with retrospective data collection from January 2001 to January 2007. The CRUSADE initiative in-
cluded high-risk patients with unstable angina and non–ST-segment elevation myocardial infarction
(NSTEMI). We retrospectively examined, among 189,065 patients with acute coronary syndrome (between
January 2001 and September 2006) in the CRUSADE initiative, the relationship of body mass index (BMI)
with patient age of first NSTEMI.
Results A total of 111,847 patients with NSTEMI were included in the final analysis. There was a strong, inverse linear
relationship between BMI and earlier age of first NSTEMI. The mean patient ages ( SD) of first NSTEMI were
74.6  14.3 years and 58.7  12.5 years for the leanest (BMI 18.5 kg/m2) and most obese (BMI 40.0
kg/m2) cohorts, respectively (p  0.0001). After adjustment for baseline demographic data, cardiac risk factors,
and medications, the age of first NSTEMI occurred 3.5, 6.8, 9.4, and 12.0 years earlier with ascending levels of
adiposity (BMI 25.1 to 30.0, 30.1 to 35.0, 35.1 to 40.0, and 40.0 kg/m2, respectively; referent 18.6 to 25.0
kg/m2) (p  0.0001 for each estimate).
Conclusions Excess adiposity is strongly related to first NSTEMI occurring prematurely. (J Am Coll Cardiol 2008;52:979–85)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.067b
e

r
c
d
i
d
c
me are in the midst of an obesity pandemic. Overall, incidence
ates of overweight have increased 2-fold and obesity more
han 3-fold over the past 50 years (1). The National Health
nd Nutrition Examination Survey in 2003 to 2004 found that
3.1% and 32.2% of Americans were overweight and obese,
espectively (2). Similarly, the Behavioral Risk Factor Surveil-
ance System reported that the prevalence of obesity increased
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hapel Hill, North Carolina; and the §University of Cincinnati College of Medicine,
incinnati, Ohio.c
Manuscript received January 7, 2008; revised manuscript received April 4, 2008,
ccepted April 7, 2008.y 24% from 2000 to 2005. However, the prevalence of
xtreme and super obesity (body mass index [BMI] 40 and
50 kg/m2) increased by 50% and 75%, 2 and 3 times faster,
espectively (3). As obesity rates increase, so do associated
See page 986
ardiac risk factors including hypertension, diabetes, and
yslipidemia as well as potentially deleterious comorbidities
ncluding sleep apnea, atrial fibrillation, and chronic kidney
isease (4,5). Additionally, obesity has recently been asso-
iated with emerging risk factors including systemic inflam-
ation (6).
Specifically, abdominal adiposity is directly related to in-reased inflammatory markers such as interleukin-6 produced
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hepatocytes to produce high-
sensitivity C-reactive protein
(hsCRP) (7). We hypothesized
that there might be a link between
excess adiposity and occurrence of
first myocardial infarction (MI) on
the basis of the expected clustering
of risk factors and presence of high
levels of systemic inflammation in
the obese (8,9).
Due to these associations, we postulated that excess
diposity might be associated with the occurrence of first
I at an earlier age. With data from the CRUSADE
Can Rapid Risk Stratification of Unstable Angina Pa-
ients Suppress Adverse Outcomes with Early Implemen-
ation of the American College of Cardiology/American
eart Association [ACC/AHA] Guidelines) registry, we
xamined the relationship between BMI and patient age
f onset of first non–ST-segment elevation myocardial
nfarction (NSTEMI), adjusting for baseline demo-
raphic data, cardiac risk factors, and medications.
ethods
he CRUSADE registry was a voluntary observational
ata collection and quality improvement initiative that
egan in November 2001, with retrospective data collec-
ion from January 2001 to January 2007 (10). The
RUSADE initiative was designed to track guideline
dherence, provide feedback about performance, and
evelop quality improvement tools to improve adherence
o ACC/AHA recommendations for the treatment of
cute ischemic symptoms.
atient population. The CRUSADE registry included
igh-risk patients with unstable angina and NSTEMI, the
conditions that collectively comprise non–ST-segment
levation acute coronary syndromes. Data were available
rom 566 sites on 189,065 patients from January 1, 2001, to
eptember 30, 2006. Patients were excluded from the
nalysis for the following reasons: unstable angina (n 
5,939), insufficient data regarding prior MI (n  2,544), a
istory of prior MI (n  50,733), missing age (n  175),
nd inadequate data for the calculation of BMI (n 7,827).
hus, we derived a final population of 111,847 with first
STEMI and calculated BMI.
nclusion criteria. All patients in the CRUSADE initia-
ive must have presented at a participating hospital within
4 h of experiencing acute ischemic symptoms (lasting for at
east 10 min) at rest. Patients with NSTEMI were required
o demonstrate a characteristic rise and fall in cardiac
roponin or creatine kinase-myocardial band with 1 con-
rmatory signs or symptoms including anginal chest pain
quivalents, ST-segment depression 0.5 mm, transient
T-segment elevation 0.5 to 1.0 mm (lasting for 10 min),
Abbreviations
and Acronyms
BMI  body mass index
hsCRP  high-sensitivity
C-reactive protein
MI  myocardial infarction
NSTEMI  non–ST-segment
elevation myocardial
infarctionr an angiographically-documented occluded culprit vessel. ratients were ineligible for the CRUSADE registry if they
ransferred to a participating hospital 24 h after the last
pisode of ischemic symptoms.
ata collection. Hospitals participating in the CRU-
ADE registry collected detailed process of care and
n-hospital outcomes data through retrospective chart
eview. Data were collected anonymously during the
nitial hospital stay with trained data collectors and
tandardized definitions. Information regarding height
nd weight were taken from the medical record, which
ould have been derived by patient self-report or direct
easurement. Because no patient identifiers were col-
ected, individual informed consent was not required.
he institutional review board of each hospital or medical
enter approved participation in the CRUSADE registry.
ll participating institutions were required to comply
ith local regulatory and privacy guidelines before begin-
ing participation in the CRUSADE registry. Blood
ressure and heart rate were recorded on presentation.
erum lipids/lipoproteins were measured within the first
4 h of hospital admission.
efinitions. Body mass index was categorized into the
ollowing groups: 18.5, 18.6 to 25.0, 25.1 to 30.0, 30.1 to
5.0, 35.1 to 40.0, and 40.0 kg/m2. Overweight was
efined as BMI 25 kg/m2, obesity class I as BMI 30.1 to
5.0 kg/m2, obesity class II as BMI 35.1 to 40.0 kg/m2, and
xtreme obesity as BMI 40 kg/m2. Hypertension was
efined as resting systolic blood pressure 140 mm Hg
nd/or diastolic blood pressure 90 mm Hg on repeated
easurements or treatment with anti-hypertensive medica-
ions. Diabetes was defined as having an established diag-
osis of diabetes mellitus or using insulin or oral hypoglyce-
ic drugs. Hyperlipidemia was defined as total cholesterol
200 mg/dl or treatment with a lipid-lowering agent.
tatistical analysis. Patient demographic data, clinical
haracteristics, and prescribed medications were compared
cross BMI groups. Continuous variables were reported as
ean  SD, and categorical variables were reported as
requencies. To test for independence across BMI groups
nd patient characteristics and care patterns, stratum-
djusted Cochran-Mantel-Hanzel statistics for trend was
sed, where stratification is by hospital. In addition, Spear-
an correlation was used to evaluate the relationship
etween age of first NSTEMI and BMI. Furthermore, the
elationship between age of first NSTEMI and BMI was
valuated, with specific reference to gender.
To investigate the factors associated with age of first
STEMI, the generalized estimating equations method
as used to adjust for patient characteristics and pre-
cribed medications including gender, BMI categories,
hite race, family history of premature coronary artery
isease, hypertension, diabetes, current/recent smoker,
yslipidemia, prior percutaneous coronary intervention,
oronary artery bypass grafting, heart failure or stroke,
enal insufficiency, electrocardiographic presentation
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September 16, 2008:979–85 Obesity and NSTEMIST-segment depression, transient ST-segment elevation
s. none), clinical signs of heart failure at hospital
dmission, presenting heart rate and systolic blood pres-
ure, and prescribed medications (aspirin, beta-blocker,
tatin, and angiotensin-converting enzyme inhibitor)
11). Because patients admitted to the same hospital tend
o be more similar to each other than those in different
ospitals (i.e., within-hospital clustering of responses),
he generalized estimating equations method was em-
loyed. A p value 0.05 was considered significant for all
ests. All analyses were performed with SAS software
version 9.1, SAS Institute, Cary, North Carolina).
esults
f 111,847 patients (59.4% men) with first NSTEMI, the
ean  SD age, body weight, and BMI were 66.1  14.4
ears, 83.2  21.8 kg (183.0 lbs), and 28.8  6.8 kg/m2,
espectively. Table 1 details baseline demographic data and
rescribed medications by ascending BMI category. There
as a strong, inverse linear relationship between BMI and
arlier patient age of first NSTEMI. The mean patient ages
f first NSTEMI were 74.6  14.3 years and 58.7  12.5
ears for the leanest (BMI 18.5 kg/m2) and most obese
BMI 40 kg/m2), respectively (p  0.0001). The patient
aseline Characteristics of the Study Group
Table 1 Baseline Characteristics of the Study Group
Variable
Underweight
<18.5
(n  3,063)
Normal Weight
18.6–25.0
(n  29,205)
Overweight
25.1–30.0
(n  39,934)
Demographics
Age (yrs) 74.6 14.3 71.2 14.6 66.1 13.9
Female (%) 2.3 47.1 33.8
Caucasian (%) 79.1 81.2 81.6
African-American (%) 12.1 8.9 8.9
Other race (%) 7.3 8.5 7.9
BMI (kg/m2) 16.5 2.0 22.6 1.7 27.4 1.4
Body weight (kg) 46.8 8.8 64.5 9.8 80.4 10.5
Body weight (lbs) 103.0 141.9 176.9
Medical history (%)
Hypertension 64.2 62.2 63.6
Diabetes mellitus 17.0 20.9 26.4
Current/recent smoker 27.3 28.3 29.2
Dyslipidemia 27.1 36.9 46.2
Family history of CAD 24.5 29.5 35.0
Prescribed medications (%)
Aspirin 36.0 36.9 37.3
Beta-blocker 29.0 29.6 28.7
Statin 17.2 23.5 28.1
ACEI 22.6 21.9 22.3
Presentation characteristics
SBP 145 (125, 166) 137 (115, 160) 141 (120, 162)
LDL-C 105 (80, 132) 90 (69, 117) 100 (76, 126)
yslipidemia was defined as a total cholesterol200mg/dl or treatment with lipid-lowering therap
r CAD in a parent or sibling before age 55 years. Systolic blood pressure (SBP) and low-density lipoprote
ACEI  angiotensin-converting enzyme inhibitor; BMI  body mass index.ge of first NSTEMI according to BMI group for men and
omen is shown in Figure 1. The correlation between age
nd BMI was r  0.30 (p  0.0001). Women were
redominant in both the leanest and most obese groups
Table 1). Rates of conventional cardiac risk factors are
hown in Table 1 and Figure 2. A history of hypertension
redominated in all BMI cohorts. However, there was a
harp rise in the frequency of diabetes from lowest to
ighest BMI group, 17.0% to 49.0%, respectively (p 
.001). Likewise, there were progressively increasing fre-
uencies of dyslipidemia with increasing BMI (p 0.0001).
verall, 28.9% were currently smoking, and this proportion
as similar across all BMI groups (p  0.76). In concor-
ance with increasing levels of cardiac risk factors, rates of
rescribed cardioprotective medications, including beta-
lockers, statins, and angiotensin-converting enzyme inhib-
tors, were all higher across ascending BMI groups (p 
.0001 for each) (Table 1).
Overall rates of prior percutaneous coronary intervention
nd coronary artery bypass surgery were relatively low,
0.8% and 11.8%, respectively. Likewise, prior stroke, heart
ailure, and renal insufficiency occurred in 8.4%, 12.1%, and
0.6%, respectively, of the total sample. All of these comor-
idities occurred in 16% of each BMI group.
BMI (kg/m2) Group
Obese
ss I: 30.1–35.0
n  23,364)
Class II: 35.1–40.0
(n  9,641)
Extremely Obese: >40.0
(n  6,640) p Value
62.8 13.2 60.8 12.8 58.7 12.5 0.0001
36.1 42.9 51.9 0.0001
81.0 79.7 77.3 0.0001
10.4 12.3 15.5 0.0001
7.1 6.4 5.7 NS
32.3 1.4 37.1 1.4 46.2 6.9 0.0001
94.0 12.4 106.3 14.7 127 26.2 0.0001
206.8 233.9 279.6
69.4 74.2 76.9 0.0001
34.4 43.7 49.0 0.0001
29.6 29.3 28.1 NS
49.6 50.2 49.3 0.0001
38.8 39.9 41.5 0.0001
37.7 36.4 35.7 0.0416
30.1 32.7 32.5 0.0001
29.9 31.3 30.4 0.0001
24.7 27.5 30.2 0.0001
45 (125, 165) 148 (128, 168) 149 (129, 169) 0.0001
06 (81, 133) 107 (83, 135) 107 (82, 134) 0.0001
ily history of coronary artery disease (CAD) was defined as reported history of myocardial infarctionCla
(
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in cholesterol (LDL-C) are presented as median (25th, 75th percentile).
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Obesity and NSTEMI September 16, 2008:979–85Upon presentation, the mean systolic blood pressure was
levated in all patient subsets, with a trend for higher levels in
scending BMI groups. Mean values were 138.6  34.1 mm
g and 150.0  31.9 mm Hg for the leanest (BMI 18.5
g/m2) and most obese (BMI40 kg/m2), respectively (p
Figure 1 Mean  SD of Patient Age of First NSTEMI
for Men and Women Across BMI Categories
p  0.0001 for both linear trends. BMI  body mass
index; NSTEMI  non–ST-segment elevated myocardial infarction.
Figure 2 Rates of Conventional Cardiac Risk Factors According
Family history (Hx) of coronary disease was defined as reported history of myocard
years. Hypertension was defined as systolic blood pressure 140 mm Hg, diastol
treated with antihypertensive medications. Diabetes mellitus was defined as existi
demia is defined as total cholesterol 200 mg/dl or current use of statin therapy.0001). In contrast, the mean resting heart rate, 86.2 
3.5 beats/min, was similar across all BMI groups. There
as ischemic ST-segment depression in 29.2%, a peak
roponin value greater than the upper limit of normal
ULN) in 95.8%, and a peak creatine kinase-myocardial
and greater than the ULN in 85.9% of patients within 24 h
f admission. The measured total cholesterol, low-density
ipoprotein cholesterol, and triglycerides were all slightly
igher across ascending BMI categories at time of presen-
ation of NSTEMI. In addition, the mean high-density
ipoprotein cholesterol was slightly lower in those with
reater degrees of adiposity (Fig. 3).
The multivariate modeling adjusted baseline character-
stics including BMI, cardiac risk factors, and prescribed
edications for the outcome of patient age at first
STEMI. Extreme obesity (BMI 40 kg/m2) had the
trongest relationship with patient age of first MI.
ompared with BMI 18.5 kg/m2, extreme obesity was
ndependently related to a 12.0-year-earlier presentation
f NSTEMI (p  0.0001) (Fig. 4). Current/recent
moking was the next most important variable with a
.7-year-earlier presentation (p  0.0001) (Fig. 4). Other
aseline factors considered in the model were found to
ave 3-year differential impact on age of first
STEMI; yet given the large sample size, all were found
MI Group
rction or coronary artery disease (CAD) in a parent or sibling before age 55
d pressure 90 mm Hg on repeated measurements, or hypertension chronically
gnosis of diabetes or current use of insulin or oral hypoglycemic agents. Dyslipi-
.0001 linear trend. BMI  body mass index.to B
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September 16, 2008:979–85 Obesity and NSTEMIo be statistically significant related to a younger age at
resentation, including dyslipidemia and prior percuta-
eous coronary intervention.
iscussion
n this large retrospective analysis of 111,847 patients in the
RUSADE initiative, approximately 36% were overweight
nd approximately 35% were obese. Extremely obese pa-
ients (BMI 40 kg/m2, approximately 6% of the sample)
xperienced their first MI on average approximately 16 years
arlier than their lean counterparts. After adjustment for
otential confounders, the age differential remained sub-
tantial at approximately 12 years. Although there were
igher rates of almost all cardiovascular risk factors in the
bese patients, these were countered with higher rates of
rescribed cardioprotective drugs at baseline. A previous
RUSADE study confirmed higher rates of risk factors and
rescribed cardioprotective drugs in this patient subset. The
nvestigators reported that obese individuals received more
ggressive coronary management, which was associated with
mproved outcomes (12).
Our multivariate analysis confirmed that higher BMI
educed the age of first NSTEMI more than any other
Figure 3 Measured Mean Lipid Values Stratified by
BMI Group at Time of Presentation of NSTEMI
High-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) choles-
terol, and serum triglycerides are presented with median and 25th and 75th
percentile values. p  0.001 for each linear trend.ariable, followed by current smoking, which resulted in a .7-year-earlier presentation. Our findings are consistent
ith a previous report in 906 consecutive patients who
resented with acute MI and had a 10.6-year age difference
etween the BMI categories of 25 and 30 kg/m2 (13).
n this study, BMI was independently related to earlier age
f presentation but not higher morbidity or mortality.
reviously reported results from the CRUSADE registry
nd the Primary Angioplasty in Acute Myocardial Infarc-
ion databases also indicate that obese patients do not have
orsened mortality or complications after MI, largely due to
heir younger age (12,14).
Obesity, particularly in those with excess intra-abdominal
dipose tissue, has been postulated to be a cardiovascular
isk state mediated through a variety of pathways. Our data
uggest that 1 pathway is a central factor in a cluster of
levated risk factors that include hypertension, diabetes, and
yslipidemia (15). A previous report from the CRUSADE
egistry found that 89.5% of all patients with NSTEMI had
t least 1 traditional cardiovascular risk factor not including
besity (16). Although not measured in our study, we
peculate that obesity plays a supporting role in “inflamma-
ion.” Intra-abdominal adiposity has been associated with
levations in interleukin-6 as well as other cytokines/
dipokines that have been linked to the pathogenesis of
therosclerotic plaque accumulation and rupture.
nterleukin-6, produced from adipocytes, is the major stim-
lus for hepatic production of hsCRP. Approximately 70%
f the variation in hsCRP is explained by adiposity along
ith associated conventional risk factors (17). Thus, the link
etween adiposity, plaque rupture, and NSTEMI might be
xplained by higher levels of systemic inflammation and
heir chronic effect on coronary atherosclerosis over time. As
result, even though subjects in our extremely obese group
Figure 4 
Factors Independently Associated With a >3-Year
Reduction in the Patient Age at Which First NSTEMI
Occurred in the CRUSADE Registry
The referent group for BMI comparisons is 18.6 to 25.0 kg/m2. The overall
mean age of first NSTEMI was 66.1  14.4 years. FHx CAD  family history of
coronary disease defined as reported history of myocardial infarction or coro-
nary artery disease in a parent or sibling before age 55 years; other abbrevia-
tions as in Figure 1.
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Obesity and NSTEMI September 16, 2008:979–85ere considerably younger than their leaner counterparts,
nflammation and the aforementioned risk factors might
rigger plaque rupture and myocardial injury prematurely in
he natural history of atherosclerosis.
The present findings have enormous public health impli-
ations. The severe and extremely obese cohorts are the
astest growing populations in the U.S. (1–3). As the
umbers in these BMI groups swell, we can anticipate
ignificantly higher rates of first NSTEMI occurring in
ounger individuals. With the mean age below 65 years for
ll categories of obesity with first NSTEMI, we can expect
 significant impact with respect to lost productivity, med-
cal disability, increased long-term medical costs, and likely
hortened survival over the following years. It seems that
besity will shift MI from a health event that commonly
ccurs in retirement years to one that occurs in the prime
orking years of life, and thus the personal, family, and
ocial implications could be staggering for Westernized
ountries.
A large proportion of the overweight and obese popula-
ions are attempting to lose weight. Voluntary weight
eduction in multiple studies has been associated with a
oncomitant decrease in all-cause and cardiac mortality
18–23). The explanation for improved outcomes is partly
xplained by favorable modifications in dietary and exercise
abits, reductions in risk factors, increased compliance with
ardioprotective medications, or combinations thereof (19).
owever, involuntary weight loss in patients after MI has
een associated with higher mortality (24). Our study could
ot make inferences with respect to individual efforts at
eight loss or weight trajectory, because we had only
ross-sectional BMI data.
tudy limitations. Our investigation has all of the limita-
ions of retrospective studies. We relied on a combination of
elf-report and measured values to calculate BMI: thus, a
ethodological source of variation around the true value.
e had no direct measure of adiposity or of lean body mass,
nd we had no measure of central adiposity—all of which
ould have made our assessment of body composition more
recise. Although BMI is highly correlated with more direct
easures of body fat in most populations, it might be a less
seful indicator of adiposity among elderly persons, who
end to shift their body weight from peripheral to central
ites (meaning an increase in waist-to-hip ratio but no
hange in BMI). We believe that a waist measurement
ight have created greater differentiation among racial
ubgroups in the normal or overweight categories, in whom
MI might not be a sensitive indicator of excess adiposity
25). Our results can only be generalized to the first
STEMI and not to all types of acute coronary syndromes,
ecause these data were available from the CRUSADE
atabase. Those with greater degrees of adiposity were
enerally treated with more cardioprotective therapies; how-
ver, we did not have information relative to the chronic
ontrol of blood pressure, dyslipidemia, and diabetes. Fi-
ally, we do not have measures of important biologic
1arameters that link adiposity to atherosclerosis, including
arkers of insulin resistance, cytokines, and inflammation.
We and others have recently demonstrated that weight
eduction in the extremely obese, as a single intervention,
an substantially reduce multiple cardiac risk factors and
easures of inflammation simultaneously (26,27). Thus,
redicted Framingham risk is markedly attenuated. How-
ver, there are no long-term studies demonstrating that
arked and sustained weight reduction in the obese in-
reases the age at which first NSTEMI can be expected.
iven the tight relationships between cardiac risk factors
nd other mechanisms by which excess adiposity promotes
therosclerosis, there is hope that significant and sustained
eight reduction in those with considerable obesity can be
 strategy to reduce cardiovascular risk and potentially
orestall the age at which first MI or cardiovascular death
ill occur (28).
onclusions
xcess adiposity is strongly related to first NSTEMI occur-
ing prematurely. These data suggest that the constellation
f established risk factors and additional metabolic derange-
ents associated with excess adiposity predispose to early
laque rupture and myocardial injury despite higher rates of
aseline cardioprotective therapies. As obesity becomes even
ore prevalent, we can expect higher rates of NSTEMI
ccurring during the working years of life.
eprint requests and correspondence: Dr. Peter A. McCul-
ough, Division of Nutrition and Preventive Medicine, William
eaumont Hospital, 4949 Coolidge Highway, Royal Oak, Mich-
gan 48073. E-mail: pmc975@yahoo.com.
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